{"nctId":"NCT00540449","briefTitle":"TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.","startDateStruct":{"date":"2008-05"},"conditions":["HIV Infections","HIV-1","Human Immunodeficiency Virus Type 1"],"count":694,"armGroups":[{"label":"Efavirenz","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Efavirenz"]},{"label":"TMC278","type":"EXPERIMENTAL","interventionNames":["Drug: TMC278"]}],"interventions":[{"name":"TMC278","otherNames":[]},{"name":"Efavirenz","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient with documented HIV-1 infection\n* Patient has never been treated with a therapeutic HIV vaccine or an ARV drug prior to screening\n* Patient's HIV-1 plasma viral load at screening is \\> 5,000 HIV-1 RNA copies/mL (assayed by RNA PCR standard specimen procedure)\n* Patient's virus is sensitive to TDF and FTC\n* Patient agrees not to start ART (antiretroviral treatment) before the baseline visit\n\nExclusion Criteria:\n\n* Previous use of ANY ARV drug for ANY length of time\n* Any documented evidence of NNRTI resistance associated mutations in patient's HIV\n* Category C AIDS defining illness, except: stable Kaposi Sarcoma, wasting syndrome if not progressive\n* Pneumocystis carinii pneumonia (PCP) that is considered not cured\n* Active TB\n* Allergy or hypersensitivity to study or background ARTs\n* Specific grade 3 or 4 toxicity\n* Kidney impairment: calculated creatinine clearance \\<50 ml/min","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 48","description":"Virological response is defined as confirmed plasma viral load less than (\\<) 50 human immunodeficiency virus-1 (HIV-1) (ribonucleic acid \\[RNA\\]) copies/milliliter (ml) at Week 48. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load \\>= 50 copies/ml after being responder) or who were never suppressed (no confirmed viral load \\<50 copies/ml).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"287","spread":null},{"groupId":"OG001","value":"285","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Virological Response (Intent-to-Treat - Snapshot, <50 Copies/ml) at Week 48","description":"The analysis is based on the last observed viral load (VL) data within the Week 48 window. Virologic response is defined as a VL\\<50 copies/ml (observed case). Missing VL was considered as non-response. Virologic Failure includes subjects who had VL\\>=50 copies/ml in the Wk48 window, subjects who discontinued early due to lack or loss of efficacy, subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy and at the time of discontinuation had a VL\\>=50 copies/ml and subjects who had a switch in background regimen that was not permitted by the protocol.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"285","spread":null},{"groupId":"OG001","value":"281","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 96","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"263","spread":null},{"groupId":"OG001","value":"271","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Virological Response (Intent-to-Treat - Snapshot, <50 Copies/ml) at Week 96","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"265","spread":null},{"groupId":"OG001","value":"268","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virological Response (Observed, <50 Copies/ml) at Last On-Treatment Visit (Post-Week 96).","description":"Virological response is defined as (observed) plasma viral load less than 50 human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid (RNA) copies per ml at the last on-treatment visit (post-Week 96).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"245","spread":null},{"groupId":"OG001","value":"261","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies/ml) at Week 48","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"297","spread":null},{"groupId":"OG001","value":"293","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies/ml) at Week 96","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"273","spread":null},{"groupId":"OG001","value":"278","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 48 and Week 96 in Absolute and Relative CD4+ Cell Counts (Using Imputed Data)","description":"Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e. change=0, Non-Completer \\[NC\\] = Failure); otherwise last observation carried forward was applied.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"195.5","spread":"151.7"},{"groupId":"OG001","value":"181.6","spread":"156.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"220.7","spread":"167.1"},{"groupId":"OG001","value":"226.7","spread":"188.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":"5.8"},{"groupId":"OG001","value":"8.7","spread":"6.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"7.5"},{"groupId":"OG001","value":"10.2","spread":"7.2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Virologic Failure for the Resistance Determination by Emerging Resistance Associated Mutations: First Available On-Treatment Genotypic Data After Failure","description":"Virologic failure for the resistance determinations was defined as lack of virologic response (never having had 2 consecutive plasma viral load \\<50 copies/mL) and plasma viral load increase of \\>=0.5 log 10 copies/mL above nadir (i.e., never suppressed), or confirmed loss of virologic response (2 consecutive plasma viral load \\>=50 copies/mL after having had 2 consecutive plasma viral load \\<50 copies/mL; i.e., rebounder), or discontinued with a last observed on-treatment plasma viral load \\>=50 copies/mL after having had 2 consecutive plasma viral load \\<50 copies/mL. For this study, treatment-emergent reverse transcriptase (RT) resistance associated mutations (RAMs) occurring in at least 2 virologic failures (for at least one treatment group) for the following lists are presented: i) Extended list of Non-nucleoside reverse transcriptase inhibitor (NNRTI RAMs) ii) IAS-USA list of Nucleoside/tide reverse transcriptase inhibitor (N\\[t\\]RTI RAMs).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":40,"n":346},"commonTop":["Dizziness","Diarrhoea","Upper respiratory tract infection","Headache","Nasopharyngitis"]}}}